Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial
European Heart Journal

Abstract
Intracoronary administration of autologous bone marrow cells (BMCs) leads to a modest improvement in cardiac function, but the effect on myocardial viability is unknown. The aim of this randomized multicentre study was to evaluate the effect of BMC therapy on myocardial viability in patients with decreased left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) and to identify predictive factors for improvement of myocardial viability.
One hundred and one patients with AMI and successful reperfusion, LVEF ≤45%, and decreased myocardial viability (resting Tl201-SPECT) were randomized to either a control group (
Intracoronary autologous BMC administration to patients with decreased LVEF after AMI was associated with improvement of myocardial viability in multivariate—but not in univariate—analysis. A large multicentre international trial is warranted to further document the efficacy of cardiac cell therapy and better define a group of patients that will benefit from this therapy.
Clinical Trial Registration Information: URL:
Contributors

Jérôme Roncalli
Author

Frédéric Mouquet
Author

Christophe Piot
Author

Jean-Noel Trochu
Author

Philippe Le Corvoisier
Author

Yannick Neuder
Author

Thierry Le Tourneau
Author

Denis Agostini
Author

Virginia Gaxotte
Author

Catherine Sportouch
Author

Michel Galinier
Author

Dominique Crochet
Author

Emmanuel Teiger
Author

Marie-Jeanne Richard
Author

Anne-Sophie Polge
Author

Jean-Paul Beregi
Author

Alain Manrique
Author

Didier Carrie
Author

Sophie Susen
Author

Bernard Klein
Author

Angelo Parini
Author

Guillaume Lamirault
Author

Pierre Croisille
Author

Hélène Rouard
Author

Philippe Bourin
Author

Jean-Michel Nguyen
Author

Béatrice Delasalle
Author

Gérald Vanzetto
Author

Eric Van Belle
Author

